Trials / Active Not Recruiting
Active Not RecruitingNCT03782207
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
A Non-Interventional, Multicenter, Multiple Cohort Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,756 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes and safety of atezolizumab for indications in the existing label in the real world setting of routine clinical practice.
Detailed description
The study will be split into separate cohorts based on the approved indications for atezolizumab treatment, excluding cisplatin ineligible participants receiving atezolizumab as first line of therapy (LOT1) for locally advanced/metastatic urothelial cancer (locally advanced/metastatic UC). The study may be amended for inclusion of new cohorts as these are approved in the participating countries. Participants will be included into each cohort based on their indication for receiving atezolizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study. |
Timeline
- Start date
- 2019-02-07
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
- First posted
- 2018-12-20
- Last updated
- 2026-01-08
Locations
258 sites across 30 countries: Argentina, Austria, Belgium, Brazil, Bulgaria, Chile, Colombia, Croatia, Egypt, Estonia, France, Hungary, India, Italy, Kuwait, Lebanon, Lithuania, Mexico, Netherlands, Oman, Pakistan, Poland, Portugal, Romania, Russia, Singapore, Slovenia, Spain, United Arab Emirates, United Kingdom
Source: ClinicalTrials.gov record NCT03782207. Inclusion in this directory is not an endorsement.